Pulling SEC filings + quote and writing the call…

SBC Medical Group Holdings Inc
Next earnings Aug 11, 2026 · consensus $0.12 EPS, $45.9M rev
Last earnings -7.7% on 2026-05-14
Statistically dirt-cheap (6.5x P/E, ~half the market cap in cash) but a CEO-relative-controlled, related-party revenue base with unremediated control weaknesses caps trust.
P/E 6.5 · price / FY diluted EPS $0.50
Middling fundamentals offset by an attractive price (~51% below fair value) — worth a look on the value angle.
On the numbers alone SBC screens as deep value: a 6.5x P/E, 1.9x sales, $164M cash against a $333M market cap (so an enterprise value near $210M for a business earning $51M), 73.3% gross margin, 38.9% operating margin and 20.5% ROE, with liabilities/equity of just 0.47x. Net income grew 9.4% to $51.0M even as revenue fell, and the asset-light franchise-management model needs almost no capital ($1.4M capex). If you take the financials at face value, the stock is priced for a business in decline while it is still highly profitable and over-capitalized.
But two things stop this from being a table-pounding buy. First, the trend is deteriorating, not stable: revenue dropped 15.5% to $174M after peaking at $205M in FY2024, and gross profit fell 18.4% — net income only rose because of below-the-line items (likely interest on the large cash pile and tax/mix), not core growth. More telling, operating cash flow was just $24.7M against $51.0M of reported net income — a wide gap that raises earnings-quality questions for a company whose 'profit' you are being asked to capitalize at face value.
Is SBC a buy? The one-page verdict, explained →
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $194M | $205M | $174M |
| Gross profit | $137M | $156M | $127M |
| Operating income | $70.7M | $70.3M | $67.5M |
| Net income | $39.4M | $46.6M | $51.0M |
| Diluted EPS | $0.42 | $0.48 | $0.50 |
| Net margin | 20.3% | 22.7% | 29.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual-meeting proxy: director elections and pay votes
Officer/director change disclosed amid ongoing governance remediation
Q1 FY26 (period Mar 31) quarterly report filed
Q1 FY26 (period Mar 31) quarterly report filed
Amended FY2025 10-K (Part III / corrections)
Entered a new material definitive agreement
FY2025 net income +9% to $51M, but revenue -16%; material weaknesses persist
FY2025 net income +9% to $51M, but revenue -16%; material weaknesses persist
Furnished corporate/other-event update; no financial change
Sources: SEC EDGAR (CIK 0001930313, latest 10-Q filed 2026-05-14) · EODHD · Proprietary analysis · as of 7/3/2026, 3:23:08 PM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 3, 2026, 11:23 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 2 sales
| 2026-04-28 | Aikawa Yoshiyuki Chairman and CEO | Sell | 465K @ $3.02 | $1.41M |
| 2026-04-21 | Aikawa Yoshiyuki Chairman and CEO | Sell | 3.10M @ $3.02 | $9.37M |
| 2026-03-06 | Aikawa Yoshiyuki Chairman and CEO | Sell | 4.42M @ $2.12 | $9.38M |
| 2024-09-30 | SAYAMA MIKE K Director | Acquired (J) | 15.0K | |
| 2024-09-19 | ZUU Co. Ltd. 10% owner | Sell | 6.20K @ $7.34 | $45.5K |
| 2024-09-17 | ZUU Co. Ltd. 10% owner | Acquired (J) | 1.50M | |
| 2024-09-17 | Aikawa Yoshiyuki Director, Chairman and CEO | Disposed (J) | 1.50M | |
| 2024-08-22 | ZUU Co. Ltd. 10% owner | Buy | 8.40K @ $10.51 | $88.3K |
| 2024-08-21 | ZUU Co. Ltd. 10% owner | Sell | 4.75K @ $11.38 | $54.1K |
| 2024-08-20 | ZUU Co. Ltd. 10% owner | Sell | 5.00K @ $11.72 | $58.6K |
| 2024-08-19 | ZUU Co. Ltd. 10% owner | Sell | 70.0K @ $11.45 | $801K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1195 tracked peers · median